StockData
Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc. (TNGX) stock

TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30128% above fair value
$22.11−2.06 (-8.52%)

Close on Nov 17, 2026Market cap $3.73BP/E –Yield –

Tango Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Tango Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $133.65M, down 2.1% year over year. For fiscal 2025 it was $132.17M, down 8.2% from the year before. The highest annual figure on record is $143.92M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$132.17M-8.2%
FY2024Dec 31, 2024$143.92M+24.9%
FY2023Dec 31, 2023$115.20M+8.8%
FY2022Dec 31, 2022$105.91M+36.4%
FY2021Dec 31, 2021$77.64M+55.3%
FY2020Dec 31, 2020$49.99M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$37.20M+13.4%
Q1 FY2026Mar 31, 2026$33.53M-8.0%
Q4 FY2025Dec 31, 2025$32.10M-5.4%
Q3 FY2025Sep 30, 2025$30.82M-7.4%
Q2 FY2025Jun 30, 2025$32.81M-15.1%
Q1 FY2025Mar 31, 2025$36.44M-4.3%
Q4 FY2024Dec 31, 2024$33.94M+8.3%
Q3 FY2024Sep 30, 2024$33.26M+22.5%
Q2 FY2024Jun 30, 2024$38.65M+34.8%
Q1 FY2024Mar 31, 2024$38.07M+35.8%
Q4 FY2023Dec 31, 2023$31.34M+7.7%
Q3 FY2023Sep 30, 2023$27.15M-5.5%
Q2 FY2023Jun 30, 2023$28.67M+20.8%
Q1 FY2023Mar 31, 2023$28.04M+15.2%
Q4 FY2022Dec 31, 2022$29.09M+34.5%
Q3 FY2022Sep 30, 2022$28.74M+31.1%
Q2 FY2022Jun 30, 2022$23.74M+24.4%
Q1 FY2022Mar 31, 2022$24.33M+62.2%
Q4 FY2021Dec 31, 2021$21.63M+43.6%
Q3 FY2021Sep 30, 2021$21.92M+68.9%
Q2 FY2021Jun 30, 2021$19.08M–
Q1 FY2021Mar 31, 2021$15.00M–
Q4 FY2020Dec 31, 2020$15.06M–
Q3 FY2020Sep 30, 2020$12.98M–

More Tango Therapeutics figures

See a number that looks wrong?